Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 92

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 92
---
 this proxy statement/prospectus. 20

COMPARATIVE PER SHARE MARKET PRICE INFORMATION NLS Common Shares trade on Nasdaq under the symbol “NLSP” and Kadimastem Ordinary Shares trades on the TASE under the symbol “KDST”. The table below sets forth the closing price per NLS Common Share on Nasdaq and per Kadimastem Ordinary Share on TASE on July 29, 2024, the date preceding public announcement of the Merger, and on February25, 2024, the latest practicable date before the date of this proxy statement/prospectus, and the equivalent price Kadimastem Ordinary Share (as determined by multiplying the closing price per share of NLS Common Share by the Exchange Ratio based on a fully diluted share split of 80%/20%) on each such date.

| Date              |     |    NLS Common 
 Share closing 
     price per 
         share 
           ($) |     |      Kadimastem 
  Ordinary Share 
         closing 
 price per share 
          ($)(1) |     |         Market 
 capitalization 
         of NLS 
   Common Share |     |         Market 
 capitalization 
  of Kadimastem 
 Ordinary Share |     |        Equivalent 
   value of Merger 
 consideration per 
        Kadimastem 
          Ordinary 
          Share(2) |
| July 29, 2024     |     |          9.35 |     |            1.59 |     |     31,040,091 |     |      6,661,646 |     |        12,321,983 |
| February 25, 2025 |     |          1.86 |     |            5.27 |     |      6,691,612 |     |     22,100,741 |     |        37,230,158 |

____________ (1)As Kadimastem Ordinary Shares trade on the TASE, there is a lack of liquidity. It is therefore difficult to determine a current active market valuation. Prior to the announcement of the deal, daily trading volume was around $1,500. (2)In accordance with the Merger Agreement on a fully diluted basis. Represents the total value of Ordinary Shares to be exchanged for NLS Common Shares as part of the Merger. (3)Moore’s valuation report for Kadimastem attached to this proxy statement/prospectus values it at USD